The Swiss holding company for private equity.
Haute Capital Partners gives every investor direct access to a curated portfolio of high-growth, non-listed Swiss companies — tradeable on BX Swiss Exchange. Full CHF denomination.
Investment Thesis
Switzerland's private markets have always created value. Access is what changes.
Switzerland has ranked first in the Global Innovation Index every year since 2011. The country's private companies — in medtech, fintech, advanced materials, and beyond — create substantial value. Yet until recently, that value has been accessible only to institutional investors and established family offices.
Haute Capital Partners was founded on a simple idea: that a well-governed listed holding company can bridge that gap. We invest in carefully selected private Swiss businesses, manage those participations actively, and give every investor the ability to gain exposure through a single listed share — tradeable on BX Swiss Exchange, denominated in Swiss francs.
Selection
We identify companies whose intrinsic potential is not yet reflected in their valuation — through proprietary deal flow, rigorous due diligence, and deep sector expertise. We invest only where the asymmetry of opportunity is genuinely compelling.
Accompaniment
Capital alone is insufficient. We work actively alongside management teams throughout the holding period — accelerating growth, strengthening governance, and opening access to new markets and strategic relationships.
Time
Patient capital is our most durable competitive advantage. We allow compounding to work — resisting short-term optimisation in favour of the kind of long-term value creation that private equity, practised with discipline, uniquely enables.
Portfolio
Companies shaping
tomorrow's Switzerland.
BioTech
BioCopy AG
Series A · CHF 500K · Q1 2026
TCRm antibody engineering · ValidaTe® AI platform · Basel
Read more
Health & AI
Care
Equity participation in progress
AI-driven preventive health & longevity platform
Read more
Deep Tech
Neolido Technology
ANAXA fire-retardant composite materials
Long-term equity participation
Read more
WealthTech
Aisot
Long-term equity participation
AI-powered quantitative investment intelligence
Read more
Finance
PB&B
Long-term equity participation
Swiss financial services & intermediation
Read more
Finance
Splint
Long-term equity participation
Fractional alternative asset platform
Read more
Why HCP
Private markets,
Without the barriers.
Private equity has historically been structured to exclude. High minimum tickets. Long lock-up periods. Opacity. Limited accountability. Haute Capital Partners applies the discipline of a private equity firm within a listed holding structure — giving every investor the same exposure that was previously reserved for institutions.
01
No Minimum
Entry
Traditional private equity requires minimum commitments of hundreds of thousands — often millions — of Swiss francs. HAUTE shares can be purchased on BX Swiss Exchange for any amount, through any standard brokerage account. The same portfolio. No minimum ticket.
02
Tradeable on
the Exchange
HAUTE shares are listed and tradeable on BX Swiss Exchange. Unlike a closed-end fund that locks capital for years, investors can adjust or exit their position through the exchange at any time — combining the substance of private equity with the accessibility of a public market.
03
Full CHF
Denomination
Every aspect of HCP's activity — capital raises, portfolio valuations, NAV reporting — is conducted in Swiss francs. No currency conversion, no translation risk. The stability of the CHF is embedded in every investment we make.
04
Transparent
Reporting
As a listed company on BX Swiss Exchange, HCP is subject to regulatory disclosure obligations. Portfolio valuations, financial statements, and significant corporate events are published and accessible to all shareholders on equal terms.
Governance
The Haute
Capital Team
News & Insights
Latest
announcements.
Haute Capital Partners Invests in BioCopy AG – AI-Powered Cancer Drug Development
Haute Capital Partners SA (BX Swiss: HAUTE) is pleased to announce a strategic investment of CHF 500’000 in BioCopy AG (biocopy.com), a Swiss research-based biotechnology company headquartered in Basel, as part of the company’s capital increase.
Haute Capital Partners SA announces the retirement of Board Member Marcel Aellen
Haute Capital Partners SA (BX Swiss: HAUTE) announces that Marcel Aellen is stepping down from the Board of Directors to retire, after several years of dedicated service.
Haute Capital invests in AI-Powered health platform CARE
Haute Capital Partners SA (BX: HAUTE) is pleased to announce a strategic investment of CHF 500’000 in CARE (care.me), a leading AI-powered preventive health platform headquartered in Switzerland, as part of its Pre Series A 2026 funding round.
Investors
Legal Documents
Browse official legal documents that define our structure, governance, and regulatory commitments.
Status
Corporate calendar
Investment Guidelines
Market & Risk Disclosures
DISCLOSURE OF SHAREHOLDINGS
This document provides transparent disclosure of significant shareholdings and any subsequent changes in notified ownership details.
07.01.2026 - Disclosure of shareholdings
2025 SEMI-ANNUAL REPORTING
Haute Capital maintained a solid balance sheet and continued to expand its asset base over the first half of 2025, despite a more challenging market environment compared to 2024.
Consolidated FS
2024 Reporting
Haute Capital closes the 2024 fiscal year with record results, marking another pivotal step in our company’s evolution.
Annual Report
Consolidated FS
Single FS
Compensation Report
2024 Semi-Annual Reporting
Haute Capital Partners reported an operating result increase of 78.84% for the first half of 2024 compared to the first half of 2023.
Consolidated FS
Single FS
2023 Reporting
Haute Capital Partners achieved remarkable milestones in 2023, underscoring our strong financial health and strategic growth.
Annual Report
Consolidated FS
Single FS
Compensation Report